Aspen to buy remaining AstraZeneca anesthetic rights for up to $766 million

LONDON (Reuters) - AstraZeneca said on Thursday it had agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa's Aspen Group for up to $766 million, a year after Aspen bought the rights outside the United States.